NO973241D0 - Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. - Google Patents

Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.

Info

Publication number
NO973241D0
NO973241D0 NO973241A NO973241A NO973241D0 NO 973241 D0 NO973241 D0 NO 973241D0 NO 973241 A NO973241 A NO 973241A NO 973241 A NO973241 A NO 973241A NO 973241 D0 NO973241 D0 NO 973241D0
Authority
NO
Norway
Prior art keywords
diphenylchromanes
hyperlipoproteinemia
hypertriglyceridemia
hypercholesterolemia
hyperlipidemia
Prior art date
Application number
NO973241A
Other languages
Norwegian (no)
Other versions
NO973241L (en
Inventor
Michael Shalmi
Niels Korsgaard
Steven Bain
Birgitte Hjort Guldhammer
Jan Ulrik Weis
Charles E Hart
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO973241D0 publication Critical patent/NO973241D0/en
Publication of NO973241L publication Critical patent/NO973241L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
NO973241A 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. NO973241L (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK4195 1995-01-13
DK4395 1995-01-13
DK6995 1995-01-20
DK76695 1995-06-30
DK76795 1995-06-30
DK77795 1995-06-30
PCT/DK1996/000014 WO1996021443A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment

Publications (2)

Publication Number Publication Date
NO973241D0 true NO973241D0 (en) 1997-07-11
NO973241L NO973241L (en) 1997-07-11

Family

ID=27545138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973241A NO973241L (en) 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.

Country Status (11)

Country Link
EP (1) EP0804189A1 (en)
JP (1) JPH10511961A (en)
CN (1) CN1168098A (en)
AU (1) AU4329296A (en)
BR (1) BR9606890A (en)
CA (1) CA2208859A1 (en)
CZ (1) CZ212397A3 (en)
HU (1) HUP9800521A3 (en)
IL (1) IL116745A (en)
NO (1) NO973241L (en)
WO (1) WO1996021443A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU3023999A (en) * 1998-03-20 1999-10-18 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for lowering plasma levels of lp(a) in a human or sub-human primate
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
WO2012061413A2 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
AU2015213484B2 (en) 2014-02-07 2015-11-05 Kazia Therapeutics Limited Functionalised benzopyran compounds and use thereof
CN116139125A (en) 2015-02-02 2023-05-23 梅制药公司 Combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543749A1 (en) * 1966-02-16 1969-12-11 Merck Ag E Process for the preparation of 3,4-cis-4-aryl-isoflavans
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
HUP9800521A3 (en) 1999-12-28
MX9705214A (en) 1997-10-31
BR9606890A (en) 1997-10-28
IL116745A0 (en) 1996-05-14
EP0804189A1 (en) 1997-11-05
HUP9800521A2 (en) 1998-12-28
CA2208859A1 (en) 1996-07-18
WO1996021443A1 (en) 1996-07-18
IL116745A (en) 1999-12-22
JPH10511961A (en) 1998-11-17
CZ212397A3 (en) 1997-11-12
NO973241L (en) 1997-07-11
AU4329296A (en) 1996-07-31
CN1168098A (en) 1997-12-17

Similar Documents

Publication Publication Date Title
NO982302D0 (en) Pharmaceutical ÷ superficial composition
NO973612D0 (en) New pharmaceutical preparation
NO962606D0 (en) Pharmaceutical composition
NO943888D0 (en) Pharmaceutical preparation
NO954694D0 (en) Dosage form for antidepressants
FI943565A (en) Novel anticoagulant polypeptides, their preparation and pharmaceutical composition containing them
BR9604632A (en) Aromatic bicyclic compounds use of at least one of the compounds pharmaceutical composition cosmetic composition and use of a cosmetic composition
EE9800065A (en) New derivatives of 5-O-desosaminyl-6-O-methylerythronolide A, their preparation method and use for the preparation of bioactive products
KR930701456A (en) Cephalosporins and homologs, preparations and pharmaceutical compositions
NO973243D0 (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases
NO973241D0 (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.
EE04681B1 (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
EE03878B1 (en) 5-O-Desosaminyl-6-O-methylerythronolide A Derivatives, Process for their Preparation and Use in the Preparation of Bioactive Compounds
FR2697155B1 (en) Total metatarsophalangeal surfacing prosthesis.
DE69614407T2 (en) PHARMACEUTICAL COMPOSITIONS
LV11727A (en) Pharmaceutical composition
NO973342D0 (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative diseases
EE03514B1 (en) A combination of compounds for the treatment of HIV infection or AIDS, its use and a pharmaceutical composition
NO973611D0 (en) New pharmaceutical preparation
EE9800140A (en) Pesticide compounds, compositions and process for their preparation
EE200000020A (en) 2,4,4-trisubstituted-1,3-dioxolanes, process for their preparation, use, pharmaceutical composition, combination and product
NO973242D0 (en) Use of 3,4-diphenylchromanes for the preparation of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiological gynecomastia
NO973341D0 (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for vasodilatory treatment or prophylaxis
IT1277117B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
ITRM930227A0 (en) IMPROVED PROCEDURE FOR THE PREPARATION OF L-(-)-CARNITINE FROM A WASTE PRODUCT HAVING THE OPPOSITE CONFIGURATION.